» Articles » PMID: 28410913

Superior Mesenteric Artery (SMA) Resection During Pancreatectomy for Malignant Disease of the Pancreas: A systematic Review

Overview
Journal HPB (Oxford)
Publisher Elsevier
Specialty Gastroenterology
Date 2017 Apr 16
PMID 28410913
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Resection of the superior mesenteric artery (SMA) during pancreatectomy is performed infrequently and is undertaken with the aim of removing non-metastatic locally advanced pancreatic tumours. SMA resection reports also encompass resection of other visceral vessels. The consequences of resection of these different arteries are not necessarily equivalent. This is a focused systematic review of the outcome of SMA resection during pancreatectomy for cancer.

Methods: A computerized search of the English language literature was undertaken for the period 1st January 2000 through 30th April 2016. The keywords "Pancreatic surgery" and "Vascular resections" were used. Thirteen studies reported 70 patients undergoing pancreatectomy with SMA resection from 10,726 undergoing pancreatectomy. Individual patient-level outcome data were available for 25.

Results: Median (range) accrual period was 132 (48-372) months. Reported peri-operative morbidity ranged from 39% to 91%. There were 5 peri-operative deaths in the 25 patients with individual-outcome data. Median survival was 11 months (95% Confidence interval 9.5-12.5 months; standard error 0.8 months).

Conclusions: SMA resection during pancreatectomy is undertaken infrequently incurring high peri-operative morbidity and mortality. Median survival is 11 (95% CI 9.5-12.5) months. In contemporary practice there is no evidence to support SMA resection during pancreatectomy.

Citing Articles

Transposition of Internal Iliac Artery to External Iliac Artery in a Case of Locally Advanced Colonic Carcinoma: A Case Report.

Tripathi M, Kumari K, Vineet K, Vadodaria D, Parekh H J Gastrointest Cancer. 2025; 56(1):64.

PMID: 39953204 DOI: 10.1007/s12029-025-01178-z.


REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives.

Boggi U, Kauffmann E, Napoli N, Barreto S, Besselink M, Fusai G Updates Surg. 2024; 76(5):1573-1591.

PMID: 38684573 PMC: 11455680. DOI: 10.1007/s13304-024-01860-0.


Surgical management of pancreatic ductal adenocarcinoma: a narrative review.

Sarfaty E, Khajoueinejad N, Zewde M, Yu A, Cohen N Transl Gastroenterol Hepatol. 2023; 8:39.

PMID: 38021357 PMC: 10643215. DOI: 10.21037/tgh-23-27.


Surgical management for elderly patients with pancreatic cancer.

Kim S Ann Surg Treat Res. 2023; 105(2):63-68.

PMID: 37564946 PMC: 10409631. DOI: 10.4174/astr.2023.105.2.63.


Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives.

Cassese G, Han H, Yoon Y, Lee J, Lee B, Cubisino A World J Gastrointest Oncol. 2023; 15(6):911-924.

PMID: 37389109 PMC: 10302990. DOI: 10.4251/wjgo.v15.i6.911.